An unusual lawsuit between the University of Pennsylvania, the university’s Abramson Cancer Center and Agios Pharmaceuticals over alleged intellectual property theft has been dropped and has been transformed into a licensing deal, according to a statement on behalf of the three groups. Penn, the Abramson Cancer Center and Agios declined to comment beyond a couple […]
Celgene’s (NASDAQ:CELG) move to withdraw its multiple myeloma drug Revlimid new application submission from the Committee for Medicinal Products for Human Use was a setback for the drug developer. But the significance of the setback was a matter of some debate between analysts that follow the company. Revlamid was initially approved by the U.S. Food […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Celgene (NASDAQ:CELG) has submitted a new drug application to the U.S. Food and Drug Administration for pomalidomide, a drug designed for multiple myeloma that does not respond to therapies. Since the drug is for an unmet need, the company stands to get a priority review. It is also planning to submit a marketing application submission […]
Celgene (NASDAQ:CELG) has agreed to a strategic discovery deal with a company that is developing antibodies to combat multiple diseases in Celgene’s latest move to diversify its portfolio. AnaptysBio uses a proprietary platform that replicates key features of the human immune system and overcomes limitations of prior antibody technologies. The San Diego, California-based company’s product […]
Celgene (NYSE:CELG) has made a $15 million strategic investment in a cancer drug developer, which gives it a seat on the company’s board and opens up collaboration opportunities down the road. Acetylon Pharmaceuticals uses histone deacetylase or HDAC inhibitors to develop small molecule cancer treatments as well as treatments for autoimmune and other diseases. The lead […]
Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached. Avila’s therapeutic platform involves the development of covalent drugs, which latch onto or bond with target cells and effectively neutralize those cells. Avila’s lead therapeutic, AVL-292, is a lymphoma and autoimmune drug in phase […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The CEO of Memorial Sloane-Kettering Cancer Research Center is the focus of a $1 billion lawsuit filed by a cancer research institute at the University of Pennsylvania for allegedly stealing the innovative cancer treatment he developed while serving as a director there. Dr. Craig Thompson was the scientific director of the Leonard and Madlyn Abramson […]
New Jersey Gov. Chris Christie’s chief of staff is returning to the pharmaceutical industry in a newly created position with Celgene (NASDAQ: CELG) next month. Richard Bagger will serve as senior vice president, corporate affairs and strategic market access, with responsibility for all government and public affairs, strategic market access, communications and patient advocacy initiatives, […]